Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

Atul Deodhar; Denis Poddubnyy; Proton Rahman; Jeorg Ermann; Tetsuya Tomita; Rebeca Bolce; Soyi Liu Leage; Andris Kronbergs; Caroline Johnson; Joana Araújo; Ann Leung; Désirée van der Heijde

doi:10.3899/jrheum.221022.C1

J Rheumatol 2023; doi:10.3899/jrheum.221022

Figure 1 was incomplete. The corrected Figure 1 appears here. This version contains all the reasons for discontinuation, including “lack of efficacy.” The “completed study” number and percentage were also corrected, and 2 footnotes were added for clarity: “^a Seven hundred seventy-three of 932 (82.9%) patients reconsented and entered COAST-Y after completing their original study. ^b Six hundred thirty-one of 932 (67.7%) patients completed 156 weeks of treatment and 12 weeks of follow-up.” This correction applies only to the March 1 2023 First Release. The correct text appears in the print and online issues.

Figure 1.

COAST-Y study design (A) and patient disposition diagram (B) through 3 years. In the randomized withdrawal and retreatment period, dose escalation was also permitted for patients who have been retreated for ≥ 12 weeks following a flare. ^a Seven hundred seventy-three of 932 (82.9%) patients reconsented and entered COAST-Y after completing their original study. ^b Six hundred thirty-one of 932 (67.7%) patients completed 156 weeks of treatment and 12 weeks of follow-up. ADA: adalimumab; AS: ankylosing spondylitis; bDMARD: biologic disease-modifying antirheumatic drug; IXE: ixekizumab; n/N: number of patients; nr-axSpA: nonradiographic axial spondyloarthritis; PBO: placebo; Q2W: every 2 weeks; Q4W: every 4 weeks; r-axSpA: radiographic axial spondyloarthritis; TNFi: tumor necrosis factor inhibitor.